Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: hip OA

Advocates for Arthritis Push for Policy Changes at Annual Event

  |  

The ACR advocates on behalf of the rheumatology community throughout the year, but it’s always especially exciting when patients join our efforts in Washington, D.C. Close to 100 patients, rheumatologists and representatives of the broader interprofessional team traveled to our nation’s capital this week to participate in the ACR’s annual Advocates for Arthritis event. Participants…

Is Concierge Medicine Right for Your Practice?

  |  

It is no surprise to practicing physicians that the healthcare landscape is becoming more and more unpredictable. Because of the volatility surrounding today’s healthcare environment, such as increasing overhead costs and decreasing reimbursement rates, many physicians are asking themselves whether there is a different, more lucrative way to practice medicine. Concierge medicine may just be…

Rheumatoid Arthritis Patients on Biologics Remain At Risk of Infection

  |  

AMSTERDAM—With new therapies coming into the marketplace, researchers are working to tease out the risk of infection for rheumatoid arthritis (RA) patients. Existing data suggest the risk of infections—even fatal ones—is real. But over time, improvements have taken hold, particularly for tuberculosis, according to an infectious disease expert at EULAR: the Annual European Congress of…

Researchers Work Toward Early ID & Treatment of Rheumatoid Arthritis

  |  

AMSTERDAM—Early identification and treatment of rheumatoid arthritis (RA) are two of the most pressing concerns in the field, an expert said at EULAR: the Annual European Congress of Rheumatology. He described the latest efforts to identify patients at risk of RA development and insights on quick referral to rheumatologists. Karim Raza, BM, BCh, PhD, Arthritis…

Immune Checkpoint Inhibitors & Immune-Related Adverse Events

Priya Chokshi, MD, Roberta Seidman, MD, Noah Levit, PhD, MD, & Steven E. Carsons, MD  |  

Immune checkpoint inhibitors (ICIs) are at the forefront of advances in cancer therapy and have shown promising results for progression-free survival. Checkpoint signaling pathways, such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1), normally regulate the immune response to promote self-tolerance and prevent tissue damage and inflammation. PD-1 is a…

Why & How to Add Advanced Practice Clinicians to Your Practice

  |  

More than two decades ago, Charles King, MD, was completing his final year of residency in internal medicine, fairly confident he was headed for a career in gastroenterology. Then he took a rotation in rheumatology. The rest, as they say, is history. “It’s a complicated field, and it requires a balance of left brained-ness and…

Compliance Means More than Just Paperwork

Anita Henderson-Sumpter, MHA, MBA, CHC, CPC  |  

Effective management of healthcare compliance requires an office compliance plan that stays current with changing government regulations, payer requirements, office operations and technology. Many still wonder, why is a compliance program needed—if something isn’t broken, don’t fix it, right? This is not always the case; compliance is an essential part of practice operations, but providing…

In Memoriam: Morris Reichlin, MD

Judith A. James, MD, PhD, & John B. Harley, MD, PhD  |  

With sadness we honor the passing of Morris Reichlin, MD. Dr. “Moe” Reichlin enjoyed a distinguished clinical, investigative, rheumatology career that spanned more than five decades. Moe was inquisitive, persistent, humble and inspiring. His achievements were many and diverse. Moe Reichlin received his BA and MD degrees from Washington University in St. Louis, where he…

Help Your Patients Live Well with Rheumatic Disease

David Daikh, MD, PhD  |  

As rheumatology professionals, we focus on how to achieve better outcomes for our patients: lower disease activity, remission, milder symptoms and prevention of joint damage or serious complications, such as heart disease. Another outcome is just as important: good quality of life. What can we do to engage our current patients and those at risk…